Merck licenses Chinese cancer drug

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
(Reuters) -Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a similar therapy from Summit Therapeutics outperformed its blockbuster Keytruda in a late-stage trial in the country.
Merck to buy rights to Chinese cancer drug for up to $3.3B
Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected to obtain licensing rights to a cancer candidate known as LM-299 from the Chinese biotech in a deal worth up to $3.
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from LaNova Medicines, a Shanghai-based firm, for $588 million upfront and as much as $2.7 billion in potential milestone payments.
Merck strikes $3.3B licensing deal for Chinese cancer drug
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.
Merck Snags Chinese Cancer Drug For Up to $3.3 Billion
Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront, plus as much as $2.7 billion in milestone payments.
Pharmalittle: We’re reading about a Merck deal, GSK cancer drug data, and more
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company
Merck in Cancer Licensing Pact With LaNova Medicines
Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company. Merck on Thursday said it has secured an exclusive global license to develop,
Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...
Merck Among 10 Companies To Announce Annual Dividend Increases In Second Half Of November
I expect 10 companies to announce their annual increases in the second half of November. Click here for a detailed analysis.
FiercePharma3d
Fierce Pharma Asia—Merck and BioNTech's I-O bispecific buys; AZ CEO's China defense
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
Merck KGaA Q3 earnings rise faster than expected on lower costs
Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by temporarily lower spending on drug ...
FierceBiotech4d
Merck pays $588M for bispecific to defend Keytruda’s kingdom from emerging threat
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.